BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Su YW, Liu PH, Hsu CY, Lee YH, Hsia CY, Ho SY, Hou MC, Chen HS, Huo TI. Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective. PLoS One 2017;12:e0174333. [PMID: 28333991 DOI: 10.1371/journal.pone.0174333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Klein S, Dufour JF. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepat Oncol 2017;4:83-98. [PMID: 30191057 DOI: 10.2217/hep-2017-0013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
2 Liu G, Xia F, Fan G, Yu J, Bao L, Zhang C, Chi R, Zhang T, Wang L, Shen F, Wang D. Type 2 diabetes mellitus worsens the prognosis of intermediate-stage hepatocellular carcinoma after transarterial chemoembolization. Diabetes Res Clin Pract 2020;169:108375. [PMID: 32827592 DOI: 10.1016/j.diabres.2020.108375] [Reference Citation Analysis]
3 Makol A, Kanthaje S, Dhiman RK, Kalra N, Chawla YK, Chakraborti A. Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma. Exp Biol Med (Maywood) 2018;243:323-6. [PMID: 29186978 DOI: 10.1177/1535370217744511] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Weinfurtner K, Dodge JL, Yao FYK, Mehta N. Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma. Transplant Direct 2020;6:e605. [PMID: 33134485 DOI: 10.1097/TXD.0000000000001060] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Chon YE, Jung KS, Kim MJ, Choi JY, An C, Park JY, Ahn SH, Kim BK, Kim SU, Park H, Hwang SK, Rim KS, Han KH, Kim DY. Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. Aliment Pharmacol Ther 2018;47:1201-12. [PMID: 29492988 DOI: 10.1111/apt.14578] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
6 Hatanaka T, Kakizaki S, Hiraoka A, Kariyama K, Tsuji K, Ishikawa T, Toyoda H, Yasuda S, Naganuma A, Tada T, Takaguchi K, Tsutsui A, Itobayashi E, Shimada N, Shibata H, Tanaka T, Nagano T, Imai M, Nakamura S, Nouso K, Kosaka H, Kaibori M, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group. The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in Japan. Cancer Med 2022. [PMID: 35608226 DOI: 10.1002/cam4.4850] [Reference Citation Analysis]
7 Ho SY, Liu PH, Hsu CY, Hsia CY, Lee YH, Lee RC, Huang YH, Lee FY, Hou MC, Tsai YJ, Huo TI. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One. 2017;12:e0180408. [PMID: 28672011 DOI: 10.1371/journal.pone.0180408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]